Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 5,241 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Germ Cell Neoplasms Clear all

Conditions: Pediatric Solid Tumors
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 25 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Melanoma
Interventions: Educational Intervention, Health Education, Media Campaign, Survey Administration; Other · Behavioral
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 12 Years and older
Enrollment: 75,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Neuroblastoma, Medulloblastoma
Interventions: Nifurtimox, Cyclophosphamide, Topotecan; Drug
Lead sponsor: Giselle Sholler; Other
Eligibility: Up to 21 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2022
U.S. locations: 15
States / cities: San Diego, California • Hartford, Connecticut • Orlando, Florida + 12 more

Conditions: Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
Interventions: melphalan, regional chemotherapy, systemic chemotherapy, hepatic artery embolization; Drug · Procedure
Lead sponsor: Delcath Systems Inc.; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 12
States / cities: Santa Monica, California • Englewood, Colorado • Tampa, Florida + 9 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Glioblastoma, Lung Carcinoma, Malignant Solid Neoplasm, Metastatic Breast Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Urothelial Carcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Microsatellite Instability High, Gastric Cancer, Esophageal Cancer
Interventions: Echopulse, Poly ICLC, Standard of Care PD-1 Therapy; Device · Drug
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Glioblastoma
Interventions: Not listed
Lead sponsor: Larissa University Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Skin Cancer, Non-Melanoma, Skin Cancer Melanoma, Mohs Micrographic Surgery
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Melanoma, Breast Neoplasms, Carcinoma, Renal Cell, Lymphoma, T-Cell, Carcinoma, Non-Small-Cell Lung
Interventions: PF-3512676; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 31
States / cities: Berkely, California • Gilroy, California • Hollister, California + 23 more

Conditions: Melanoma, Soft Tissue Sarcoma
Interventions: Autologous total tumor mRNA loaded DOTAP liposome vaccine; Biological
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Malignant Melanoma
Interventions: RO5185426; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 11
States / cities: La Jolla, California • San Francisco, California • Stanford, California + 8 more

Conditions: Choroidal Melanoma
Interventions: 1000CsK Silicon Oil Tamponade; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Brain Tumor, Recurrent, Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma
Interventions: Cytoreductive surgery, Perifosine, Temsirolimus; Procedure · Drug
Lead sponsor: Andrew B Lassman, MD; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 2
States / cities: New York, New York

Conditions: Brain and Central Nervous System Tumors
Interventions: dasatinib, temozolomide, placebo, radiation therapy; Drug · Other · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 207
States / cities: Hartford, Connecticut • Jacksonville, Florida • Columbus, Georgia + 135 more

Conditions: Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma
Interventions: TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Cyclophosphamide + Fludarabine Lymphodepletive Conditioning, Dose-Intensified TMZ, Td vaccine, Autologous Hematopoietic Stem Cells (HSC); Biological · Drug
Lead sponsor: University of Florida; Other
Eligibility: 3 Years to 30 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Recurrent Glioblastoma Multiforme
Interventions: 131-I-chTNT-1/B MAB; Drug
Lead sponsor: Peregrine Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 4
States / cities: Phoenix, Arizona • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more

Conditions: Merkel Cell Carcinoma, Small Cell Lung Cancer
Interventions: XmAb18087, XmAb18087 ± Pembrolizumab; Biological · Drug
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • Lebanon, New Hampshire + 3 more

Conditions: Glioma
Interventions: Fractionated Radiation, Temozolomide, MRI; Radiation · Drug · Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Glioblastoma
Interventions: Dendritic Cell Immunotherapy; Biological
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent, Ependymoma, Ependymoma Malignant, Ependymoma of Brain
Interventions: Specialized Tumor Board Treatment Plan, Combinations; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 12 Months to 39 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 5 more

Conditions: Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
Interventions: Conventional Surgery, Laboratory Biomarker Analysis, Sorafenib Tosylate, Temsirolimus; Procedure · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 190
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Hartford, Connecticut + 118 more

Conditions: Newly Diagnosed Glioblastoma
Interventions: Marizomib, Temozolomide, radiotherapy; Drug · Radiation
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC; Network
Eligibility: 18 Years and older
Enrollment: 749 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 9
States / cities: Scottsdale, Arizona • Orange, California • San Francisco, California + 6 more

Conditions: Melanoma (Skin)
Interventions: incomplete Freund's adjuvant, melanoma helper peptide vaccine, multi-epitope melanoma peptide vaccine, sargramostim, tetanus peptide melanoma vaccine; Biological
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 65
States / cities: Palo Alto, California • Stanford, California • Lewes, Delaware + 50 more

Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Oligodendroglioma, Recurrent Adult Brain Tumor
Interventions: erlotinib hydrochloride, isotretinoin, laboratory biomarker analysis, protein expression analysis; Drug · Other · Genetic
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Search by objective public record fields.

Molecular Analysis Of Solid Tumors

War on Melanoma™ Public Health & Education Campaign

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

A Multicenter, Prospective Study for Glioblastoma Patients

Interpolated Flap Study

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization

A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Safety and Efficacy of Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma

Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)

Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme

Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer

Image-Based Quantitative Assessment of Acute Radiation-Induced Changes in Glioma

Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma